Evidence map›Paper›PMID 41025792›Full record

ArticleJournal of virology2025

Developing an eVLP mRNA vaccine for respiratory syncytial virus with enhanced pre-fusion targeting humoral responses.

Lei Sun, Mengting Huang, Simin Feng, Wei Zhang, Yun Quan, Ruyi Chen, Yupeng Yang, Haidong Xu, Wansheng Li, Qianyu Pan and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Lei Sun *State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.ORCID 0000-0002-3318-9458
Mengting Huang *State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.ORCID 0009-0007-2991-7719
Simin Feng *Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, China.ORCID 0009-0003-5830-3207
Wei ZhangGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, China.
Yun QuanState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.
Ruyi ChenGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, China.
Yupeng YangState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.
Haidong XuState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.
Wansheng LiState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.
Qianyu PanState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.
Xinwen ChenState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.ORCID 0000-0002-4052-8155
Danyang ZhangGuangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, China.
Bin YuanState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.
Jincun ZhaoState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.ORCID 0000-0003-2515-5589
Zhongfang WangState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.ORCID 0000-0003-3236-5170
Jinzhong LinState Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.
Wei PengState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.
Martin LudlowResearch Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover, Hannover, Germany.ORCID 0000-0002-0061-1106
Qiong ZhangState Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.ORCID 0000-0001-9790-3625

Funding

Guangdong Provincial Department of Science and Technology, The Pearl River Talent Recruitment Program 2023QN10Y266Guangdong Provincial Department of Science and Technology, The Pearl River Talent Recruitment Program 2023QN10Y469Guangzhou National Laboratory GZNL2023A01006Guangzhou National Laboratory QNPG23-05Guangzhou National Laboratory QNPG24-13Guangzhou National Laboratory SRPG22-002Guangzhou National Laboratory YW-JCYJ0612National Natural Science Foundation of China 82402135
6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease (LRTD) in infants, the elderly, and immunocompromised individuals. In this study, we leveraged the innovative EABR (ESCRT- and ALIX-binding region) vaccine technology to develop a pre-fusion (Pre-F)-based RSV mRNA vaccine (Pre-F-EABR) that encodes self-assembling enveloped virus-like particles (eVLPs). IMPORTANCE: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in infants, the elderly, and immunocompromised individuals. It is well-established that enhancing the neutralizing antibody levels and Th1-biased cellular immune responses can potentially improve the efficacy and safety of RSV vaccines. In this study, we developed an RSV pre-fusion protein-based mRNA vaccine that encodes self-assembling enveloped virus-like particles. Mice immunized with this vaccine showed significantly enhanced pre-fusion protein-targeted humoral responses and improved protection against RSV infection compared to the conventional RSV mRNA vaccine. Additionally, this vaccine demonstrated a considerably stronger neutralizing ability against contemporary clinical RSV isolates and induced more robust Th1-biased cellular immune responses, suggesting its potential as a promising RSV vaccine candidate.

Indexed as

Immunity, HumoralRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesVaccines, Virus-Like ParticleViral Fusion ProteinsAnimalsAntibodies, NeutralizingAntibodies, ViralFemaleHumansImmunity, CellularMiceMice, Inbred BALB CNanoparticlesRNA, MessengerAntibodies, NeutralizingAntibodies, ViralRespiratory Syncytial Virus VaccinesRNA, MessengerVaccines, Virus-Like ParticleViral Fusion ProteinsEABReVLPsimmune responsesmRNA vaccinerespiratory syncytial virus

Identifiers

PMID41025792
PMCPMC12548431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.